The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic kidney disease with or without albuminuria have not been well studied. ⋯ In patients with diabetes and chronic kidney disease, with or without albuminuria, sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo but was associated with adverse events. (Funded by Sanofi and Lexicon Pharmaceuticals; SCORED ClinicalTrials.gov number, NCT03315143.).
-
Comment Letter
Hydroxychloroquine with or without Azithromycin in Covid-19.